Dermatology · Detroit area, MI
Dermatology and skin studies in Detroit area, MI
26 recruiting studies have a site in the Detroit area. This page includes nearby cities such as Ann Arbor, Southfield, Troy, Royal Oak.
26 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Pfizer
- Location
- Troy, MI + 4 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1
Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section
Wayne State University
- Location
- Detroit, MI
- Eligibility basics
- Ages 18–50 · Women only
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- Detroit, MI + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Sagimet Biosciences Inc.
- Location
- Clinton Township, MI + 17 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Apogee Therapeutics, Inc.
- Location
- Detroit, MI + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Pfizer
- Location
- Ypsilanti, MI + 11 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2/Phase 3
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
Pelage Pharmaceuticals, Inc.
- Location
- Clinton Township, MI + 26 other US sites
- Eligibility basics
- Ages 18–55 · Men only
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Auburn Hills, MI + 90 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 2
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Novartis Pharmaceuticals
- Location
- Ann Arbor, MI + 23 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Ann Arbor, MI + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
- Location
- Auburn Hills, MI + 23 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Eli Lilly and Company
- Location
- Troy, MI + 8 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Eli Lilly and Company
- Location
- Troy, MI + 17 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU…
Celldex Therapeutics
- Location
- Troy, MI + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
LEO Pharma
- Location
- West Bloomfield, MI + 6 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Novartis Pharmaceuticals
- Location
- Troy, MI + 22 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Enveda Therapeutics
- Location
- Auburn Hills, MI + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Beijing InnoCare Pharma Tech Co., Ltd.
- Location
- Auburn Hills, MI + 13 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
Pfizer
- Location
- Troy, MI + 4 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice…
Eli Lilly and Company
- Location
- Ann Arbor, MI + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb
- Location
- Detroit, MI + 26 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 4
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
Bausch Health Americas, Inc.
- Location
- Clinton Township, MI + 13 other US sites
- Eligibility basics
- Ages 9–11
- RecruitingPhase 2
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Pfizer
- Location
- Ann Arbor, MI + 13 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc.
- Location
- Auburn Hills, MI + 53 other US sites
- Eligibility basics
- Ages 12–17
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.